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5 clotrimazole, itraconazole, sertraline, and raloxifene (Walsky et al., 2006) . However, predicting how pharmaceuticals interact with 2B6 has been complicated due to its polymorphic nature.
With 28 known alleles leading to different gene products, expression levels and drug metabolism vary widely across populations (Zanger et al., 2007) . The most commonly occurring variants are single nucleotide polymorphisms (SNPs) that lead to the Q172H, K262R and R487C mutants (Zanger et al., 2007) . Specifically, the K262R variant shows a greater than 3-fold increase in the K i values for clopidogrel, itraconazole, and raloxifene and a 6-fold increase in the K i of sertraline (Talakad et al., 2009) . Unlike wild type 2B6, the K262R variant is not inactivated by phencyclidine (Shebley and Hollenberg, 2007) , 17-ethynylestradiol, or efavirenz (Bumpus and Hollenberg, 2008) . In order to predict population differences in steroid, drug, and xenobiotic metabolism, a better understanding of 2B6 structure-function relationships is required.
Until now, structural data related to 2B6 function have been limited to site-directed mutagenesis studies (Domanski et al., 1999; Spatzenegger et al., 2003) , homology models based on other mammalian P450s (Domanski et al., 1999; Wang and Halpert, 2002) , or mapping 2B6 residues onto structures of 2B4 Talakad et al., 2009; , with which 2B6 shares 78% amino acid sequence identity. Additionally, methods that infer enzyme structural data based on molecular properties of known substrates have also proven useful (Ekins et al., 2008) . However, x-ray crystallography remains the best tool for obtaining atomic-level details. Numerous mammalian P450 structures have been determined by crystallographic methods (Ekins et al., 2008; Johnson and Stout, 2005; . However, 2B6 and 3A5 remained as the only human drug metabolizing P450s without crystal structures. There are currently five crystal structures of the highly related 2B4 enzyme (Gay et al., 2009; Scott et al., 2003; Scott et al., 2004; Zhao et al., 2007; . These This article has not been copyedited and formatted. The final version may differ from this version. P450s might exhibit similar plasticity. For example, a crystal structure of 2B4 bound to the inhibitor 4-(4-chlorophenyl)imidazole (4-CPI) (Scott et al., 2004) shows the enzyme in a closed conformation in contrast to open complexes with the larger inhibitors 1-(4-phenyl)benzylimidazole (1-PBI) (Gay et al., 2009) or bifonazole . X-ray crystallography requires large amounts of highly pure protein. In the past, obtaining sufficient amounts of protein for growing 2B6 crystals has been difficult because of problems with heterologous expression and purification (Hanna et al., 2000) . N-terminal truncation and modification (Scott et al., 2001) , chaperone coexpression (Mitsuda and Iwasaki, 2006) , and internal modifications based on comparison with other P450 2B enzymes have greatly improved the yield of high quality, purified 2B6. Mutational studies have also led to constructs with greater thermal and chemical stability as well as increased solubility . Years of combined research have finally led to a system that allows for the expression, purification, and crystallization of 2B6. Here, we present the first crystal structure of 2B6 in complex with 4-CPI at 2.0 Å resolution. Along with its 2B4 counterpart, P450 2B6 also provides the first example of two crystal structures of mammalian P450 orthologs bound to the same compound. This unique result allows for very a specific comparison of the rabbit and human enzymes and analysis of subtle differences in their structures.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Materials. Imidazole and pyridine compounds were obtained from Sigma-Aldrich (St. Louis, MO). 5-Cyclo-hexylpentyl-β-D-maltoside (Cymal-5) was from Anatrace (Maumee, OH). Fifty kDa molecular weight cutoff Amicon Ultra filtration devices were from Millipore (Billerica, MA). Clear Strategy Screen I HT-96 was from Molecular Dimensions (Apopka, FL). The pGro7 plasmid was acquired from Takara Bio (Shiba, Japan). Ni-NTA affinity resin was from Qiagen (Valencia, CA). Macroprep CM cation exchange resin was from Bio-Rad Laboratories (Hercules, CA). E. Coli JM109 competent cells were from Stratagene (La Jolla, CA). The synthesis of the facial amphiphile 3α,7α,12α-tris[(β-D-maltopyranosyl)ethyloxy]cholane (232-chol) was performed essentially according to a previously described method (Zhang et al., 2007) and will be reported in more detail elsewhere.
Mutagenesis, Protein Expression and Purification.
To create the Y226H, K262R double mutant construct, P450 2B6dH was used as a template. The Y226H primers 5'-CTCTGGCTTCTTGAAACACTTTCCTGGGGCACAC-3' and 5'-GTGTGCCCCAGGAAAGTGTTTCAAGAAGCCAGAG-3' and K262R primers 5'-CCCAGCGCCCCCAGGGACCTCATCGAC-3' and 5'-GTCGATGAGGTC CCTGGGGGCGCTGGG-3' were used in subsequent PCR procedures. DNA sequences were analyzed by the Protein Chemistry Laboratory, University of Texas Medical Branch, Galveston, TX to confirm the inclusion of both mutations.
Cytochrome P450 2B6dH (Y226H, K262R) was co-expressed with the chaperone GroES/EL (pGro7 plasmid) in E. coli JM109 cells as previously described (Talakad et al., 2009) and purified by modifying the same protocol. The pellet was resuspended in 10% of the original This article has not been copyedited and formatted. The final version may differ from this version. glycerol, 10 mM BME, and 0.5 mM PMSF. The resuspended cells were further treated with lysozyme (0.2 mg/mL) and stirred for 30 min at 4 °C, followed by a brief centrifugation for 15 min at 7000 rpm in a JA-14 rotor in an Avanti J-26 XPI Centrifuge (Beckman Coulter, Inc., Fullerton, CA). Spheroplasts were again resuspended in 5% of the original culture volume in buffer containing 500 mM potassium phosphate (pH 7.4 at 4 o C), 20% (v/v) glycerol, 10 mM BME, and 0.5 mM PMSF and were sonicated for 3 x 45 s on ice. The membrane pellet was separated by centrifugation for 10 min at 7000 rpm in the same centrifuge as above and Cymal-5 was added to the supernatant at a final concentration of 4.8 mM. This was allowed to stir for 30 min at 4 °C prior to ultracentrifugation for 45 min at 41000 rpm using a fixed-angle Ti 50.2 rotor in an Optima L-80 XP Ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA). The P450 concentration in the supernatant was determined from the reduced CO difference spectra.
His-tagged 2B6dH (Y226H, K262R) was purified using Ni-NTA resin in the presence of detergent Cymal-5. The column was washed with buffer containing 100 mM potassium phosphate (pH 7.4 at 4 ºC), 100 mM NaCl, 20% (v/v) glycerol, 10 mM BME, 0.5 mM PMSF, 4.8 mM Cymal-5 and 1 mM histidine, and the protein was eluted using the above buffer containing 60 mM histidine. The P450 containing fractions were pooled and diluted 10-fold in the buffer with 5 mM potassium phosphate (pH 7.4 at 4 ºC), 20% (v/v) glycerol, 1mM EDTA, 0.2 mM DTT, 0.5 mM PMSF and 4.8 mM Cymal-5, prior to loading onto a Macroprep CM cation exchange column. The column was washed using 5 mM potassium phosphate (pH 7.4 at 4 ºC), 20 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA and 0.2 mM DTT and the protein was eluted with high salt buffer containing 50 mM potassium phosphate (pH 7.4 at 4 ºC), 500 mM NaCl, 20% (v/v) Methanol was used as a cosolvent to dissolve 4-CPI and was maintained at a concentration less than 2% for the titration experiments. When the apparent binding constants (K D ) were less than the concentration of protein, titration curves were fit to a derivative of the velocity quadratic equation or "tight binding" equation: Temperature Stability Assay. Thermal stability of P450 was measured in a reaction mixture containing 1 µM protein in 100 mM NaOH-HEPES buffer, pH 7.4. Thermal inactivation was determined from a series of absorbance spectra in the 340-to 700-nm range as a function of temperature between 25 and 70°C with 2.5-5°C intervals and a 2-min equilibration at each temperature. Determination of total concentration of the heme protein was done by nonlinear least-squares approximation of the spectra using a linear combination of spectral standards of P450 2B4 low-spin, high-spin, and P420 states. All data treatment and fitting of the titration curves were performed with our SpectraLab software package. Fitting of the temperature profile curves was performed by regression analysis using Sigma Plot. The mid point of thermal transition temperature (T m ) was obtained by fitting the inactivation profile to sigmoidal two-state model and four-parameter logistic curve . Crystals were transferred to a solution containing 100 mM sodium acetate (pH 5.5), 200 mM potassium thiocyanate, 10% (w/v) polyethylene glycol 1,000, 10% (w/v) polyethylene glycol 8,000, and 500 mM sucrose for cryoprotection before rapid cooling in liquid nitrogen.
Initial diffraction patterns at the Stanford Synchrotron Radiation Lightsource (Stanford, CA)
showed numerous ice rings. To remove the ice rings, the crystal was annealed by blocking the stream of liquid nitrogen for 4 seconds while the crystal was mounted on the goniometer. Two data sets were collected remotely at beamline 11-1 of SSRL. The first data set was collected using 20-second exposures and the second data set was collected using 30-second exposures.
Both data sets were collected using 1° oscillations over 180° total at 100 K on a Quantum CCD detector (Area Detector Systems Corp., Poway, CA). Images were integrated using iMosflm (Leslie, 1999) . The first data set was integrated to 2.0 Å. The second data set was split into two parts; the first 90 frames were integrated to 2.0 Å and the last 90 frames were integrated to 2.1 Å as the crystal began to decay in the X-ray beam. The three integrated portions were merged in CCP4i and scaled using SCALA (Bailey, 1994) .
This article has not been copyedited and formatted. The final version may differ from this version. McCoy, 2007) . These regions correspond to mobile, plastic regions in 2B4 (Gay et al., 2009; and are expected to behave similarly in 2B6. The initial model was subjected to a rigid body refinement and a restrained refinement using the software REFMAC (Bailey, 1994) before model building in COOT (Emsley and Cowtan, 2004 ) began using 2Fo-Fc electron density maps contoured at 1-σ. The heme, 4-CPI, and regions deleted from the molecular replacement model were clearly defined in the electron density. The protein model was modified to reflect amino acid differences between the 2B4 and 2B6 sequences. The iterative process of model building and refinement was continued until a final R-factor of 17.8 % and an R free of 22.8% were reached. Refinement statistics are summarized in Table 1 .
Atomic coordinates and structure factors have been deposited in the Protein Data Bank (accession code 3IBD).
Ligand Docking. Prior to docking the inhibitor ticlopidine, the 2B6dH (Y226H, K262R) structure file was modified. Any residues not modeled into the experimental electron density were added using COOT and 4-CPI, Cymal-5, and thiocyanate ions were removed from the PDB file. The Autodock4 (Morris et al., 1998) script used to simulate ligand binding added all hydrogen atoms to the protein and ligand PDB files, removed any water molecules, and was run with default settings. Small molecule charges were set to Gasteiger. Charges found on the heme were modified using a separate script citing values previously reported (Helms and Wade, 1995) .
This article has not been copyedited and formatted. The final version may differ from this version. The docking experiment included 100 events using a grid size of 70 Å x 70 Å x 70 Å with 0.375 Å spacing.
Figures. All protein model figures were generated using PyMOL (DeLano, 2002) .
Results
Construct Selection. Structural studies of 2B6 have lagged behind those on other 2B enzymes due to low expression levels (Hanna et al., 2000) and low thermal stability compared with 2B1, 2B4 and 2B11 . Decreased stability is associated with P420 formation and aggregation during purification. Initial improvements in expression arose by applying the same N-terminal truncations and modifications used to enhance expression in 2C3 (von Wachenfeldt et al., 1997) and 2C5 (Cosme and Johnson, 2000) to produce P450 2B6dH (Scott et al., 2001) and by co-expression with the chaperone GroEL/ES (Mitsuda and Iwasaki, 2006) . However, the instability of 2B6 caused aggregation during purification and precipitation during crystallization trials.
Recently, efforts to rationally engineer 2B6dH mutants based on sequence comparisons with 2B1, 2B4, and 2B11 have shown that mutants such as L264F can be created that exhibit increased expression and thermal stability while retaining substrate specificity . However, this mutant showed no advantage over 2B6dH in crystallization trials. Based on reports of enhanced solubility of the naturally occurring genetic variant K262R (Bumpus et al., 2005) , this mutant was also tested. However, the decreased temperature stability was a liability (Table 2) . Unfortunately, combining the K262R and L264F mutations resulted in a construct with a lower T m than the K262R single mutant. A search for other mutants with enhanced stability yielded Y226H, which like the L264F mutant maintained sensitivity to inhibition by a variety of ligands (Table 3 ). The Y226H, K262R double mutant retained the desirable traits from both single mutants, showing increased expression, thermal stability, and solubility. 4-CPI was chosen for crystallization experiments because it is the tightest binding nitrogenous inhibitor of 2B6 (Table 3) Purification and Crystallization. Initial crystallization trials were performed at ~30 mg protein/ml, which was suitable for 2B4dH crystallization and that of many other mammalian P450s (Porubsky et al., 2008; Sansen et al., 2007; Schoch et al., 2004; Williams et al., 2000) . molecules was observed in separate hydrophobic pockets, and was modeled just prior to the final rounds of refinement. The maltose groups were not present in the electron density for either detergent molecule. In addition, four thiocyanate ions were also found in the electron density and were added to the model at the same time. While 232-chol was necessary for crystallization, it was not observed in the electron density maps. Refinement statistics are summarized in Table 1 .
The tertiary structure of 2B6 is similar to that of other mammalian P450s, consisting of a Comparison to P450 2B4. The length and placement of secondary structural elements in 2B6 is almost identical to that found in the 2B4−4-CPI complex (Fig. 2) . Plastic regions identified in 2B4 (the B/C loop and F through G helices) adopt similar conformations in 2B6, yielding an RMSD of 0.65 Å in a C α overlay (Fig. 3a) . This small RMSD is even less than that found between the 1-CPI and 4-CPI structures of 2B4 (0.76 Å), indicating that the ability to conform to these particular ligands outweighs protein sequence differences found between 2B4 and 2B6.
This closed conformation is similar to that also found in other family 2 enzymes 2C5 (Williams et al., 2000) , 2C8 (Schoch et al., 2004) , and 2C9 (Williams et al., 2003) .
In the 4-CPI complexes of both 2B6 and 2B4, the heme is held into place through an iron-thiolate bond at residue Cys 436 and is surrounded by the C, I, and L helices. (Nishiya et al., 2009) , and each 4-CPI contact residue listed in Table 4 also falls within a 5 Å radius of the docked inhibitor. In addition, 16 poses showed alternate ligand orientations and mean energies from -7.57 to -7.27 kcal/mol.
Discussion
This article has not been copyedited and formatted. The final version may differ from this version. Prior to the determination of the 2B6 structure, efforts to identify active site residues and other residues responsible for substrate recognition and specificity were limited to mutagenesis studies and homology models based on other mammalian P450s. Of the 10 residues within 5 Å of 4-CPI in the 2B6 active site residues 209, 363, 367, and 477 were shown to be important for the oxidation of 7-butoxycoumarin (Spatzenegger et al., 2003) and residues 363 and 477 for the oxidation of RP 73401 (Domanski et al., 1999) . A homology model based on the structure of 2C5 and data gathered from mutagenesis of 2B1 (Wang and Halpert, 2002) identified residues 114, 115, 206, 209, 297, 298, 302, 363, 367 and 477 as taking part in substrate recognition.
Residues 103, 290, 294, 478, and 480 are also shown in the active site of this model; however these residues do not interact with 4-CPI in the crystal structure. The omission of 4-CPI interaction partners or the inclusion of residues found outside the 4-CPI binding site in these models likely highlights the variability of P450 active sites when confronted with substrates of different sizes and shapes. Overall, mapping residues onto models based on previously determined 2B4 crystal structures Talakad et al., 2009; has resulted in the most accurate prediction of the location of 2B6 residues.
Among 2B6 active site residues of particular interest is Leu 363, which is Ile in 2B4 and Val in 2B1. In 2B6, CG1 and CD1 of Leu 363 mimic the corresponding atoms of Ile 363 in 2B4
( Fig. 3b) While most of the residues that define the 4-CPI binding site in 2B6 are hydrophobic, there are two residues with polar side chains, Glu 301 and Thr 302. In the 4-CPI complex with 2B4, Glu 301 makes a hydrogen bond with a free azole nitrogen of the ligand (Scott et al., 2004) .
However, in the 4-CPI complex with 2B6, Glu 301 moves out of the active site and contacts a nearby water molecule. Interestingly, in the 2B4 complex with 1-CPI, which lacks a free nitrogen for hydrogen bonding, Glu 301 also moves out of the active site, in this case interacting with His 172 , which is Gln in 2B6. In the 2B6 structure, the apparent small shift in 4-CPI orientation toward Phe 206 (Fig. 3b) is allowed because Glu 301 does not occupy the space that it does in the 2B4 complex. Residue 172 is a known SNP location in 2B6, with the Q172H mutant being most prevalent (Zanger et al., 2007) . Since Glu 301 may interact with the side chain of residue 172, the identity of that residue, along with additional nearby SNP residues 167 and 168 (Fig. 5) could affect ligand binding.
Additional SNPs even farther away from the active site also affect substrate specificity and catalysis. The 2B6 K262R genetic variant occurs to varying degrees in human populations.
Typically, frequencies range from 17 to 63% (Zanger et al., 2007) . With increasing investigations reporting altered drug metabolism for this and other SNP gene products in 2B6, it is imperative to determine how these mutations affect enzyme structure-function relations. The differences found in the pattern of heme pyrrole-phenyldiazene adducts indicate that the active site topology of K262R could differ from wild type (Bumpus and Hollenberg, 2008) . Without a This article has not been copyedited and formatted. The final version may differ from this version. wild type structure for reference, it is impossible to describe those differences in atomic detail at this time. However, most SNPs in 2B6 occur far from the active site (Fig. 5) , indicating that any functional effects are transduced via long-range hydrogen-bonding networks or through subtle differences in the placement of secondary structural elements.
The K262R mutation occurs on the G/H loop, approximately 25 Å from the active site and does not affect the IC 50 (Talakad et al., 2009) or Ks of 4-CPI (data not shown). However, differences have been found with other ligands (Shebley and Hollenberg, 2007; Talakad et al., 2009) . A direct connection to the active site through polar interactions could not be found in the current structure. Interestingly, the local environment of residue 262 is highly conserved. In both 2B4 and 2B6dH (H226Y, K262R), Arg 262 is part of a small hydrogen-bonding network that includes His 252, Thr 255, Asp 263, and Asp 266. An alignment of 10 2B enzymes (not shown)
indicates that the only divergence in this cluster of residues is Lys 262 in 2B6. Despite the high degree of mobility of this region in the series of 2B4 crystal structures (Gay et al., 2009; Scott et al., 2004; , the residues in this network maintain their interactions in every 2B4 structure (Fig. 6 ) and the present 2B6 structure as well, indicating that the G and H helices move in concert. The concerted movement of the G and H helices, which could be affected by this hydrogen-bonding network, could influence the orientation of active site residues on the G helix.
Alternatively, the identity of residue 262 was previously found to affect 2B6 affinity for cytochrome P450 reductase, but not by an appreciable amount (Bumpus and Hollenberg, 2008 ).
Perhaps interactions between the H helix and P450 redox partners are transduced to the G helix and thus to the active site through this connection. Replacing Arg 262 with a lysine, as in wild type 2B6, breaks this network of hydrogen bonds, likely destabilizing this region and could affect either of these hypothesized scenarios.
This article has not been copyedited and formatted. The final version may differ from this version. arise from species differences in the protein sequence, but they could also be a result of crystal packing. Interestingly, even though the 2B4 and 2B6 crystals were grown under different conditions, the thermodynamics of the 2B−4-CPI complex formation overcomes any differences caused by the pH and salt content of the crystallization solution as well as crystal lattice contacts.
If the 2C differences are sequence based and not an effect of crystal packing, structural variations could give insight into enzyme evolution. It is possible that changes in the 2B4/2B6 pair have occurred more slowly than the less structurally related 2C5/2C9 pair.
In conclusion, the 2.0 Å structure of 2B6dH(Y226H, K262R) in complex with the inhibitor 4-CPI is the first view of this human enzyme that has been gaining relevance as the list of important xenobiotic substrates has grown. Given a difference of ~100 amino acids in their sequences, the striking structural similarities between 2B6 and 2B4 were surprising. In this case, it appears that the strong interactions with 4-CPI are the driving force to assume the observed conformation and overwhelm any differences due to amino acid substitutions. This particular , and D266 appears to link the G and H helices together throughout these shifts in secondary structure placement. These same interactions are also seen in the present 2B6 structure.
This article has not been copyedited and formatted. The final version may differ from this version. 4-phenylpyridine (4-PP) 5.6 ± 1.6 3.5 ± 1.3 5.7 ± 1.5
4-(4-chlorophenyl)pyridine (4-CBP) 0.32 ± 0.12 0.29 ± 0.10 0.7 ± 0.28 4-(4-chlorophenyl)imidazole (4-CPI) 0.26 ± 0.10 0.27 ± 0.08 0.37 ± 0.07 1-(4-chlorophenyl)imidazole (1-CPI) 0.53 ± 0.013 0.54 ± 0.14 0.37 ± 0.05 1-benzylimdazole (1-BI) 7.5 ± 1.2 6.2 ± 0.3 5.5 ± 1.2 4-phenylimidazole (4-PI) 1.4 ± 0.9 2.5 ± 0.5 1.7 ± 0.9 a Enzyme inhibition was assessed using 7-methoxy-4-(trifluoromethyl)coumarin (7-MFC) O-deethylation as described earlier (Talakad et al., 2009) . In brief, the reaction mixture contained 150 μ M 7-MFC in the standard reconstitution system (P450: NADPH-cytochrome P450 reductase: cytochrome b 5 , 1:4:2) at 5 pmol P450 in 50 mM Hepes, pH 7.4, 15 mM MgCl 2 , and 2% MeOH. The reaction was performed at 37 °C for 5 min using 1 mM NADPH. Nonlinear regression analysis was performed to fit the data using a four-parameter logistic function to derive the IC 50 values. 
